X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs IPCA LABS - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA IPCA LABS FULFORD INDIA/
IPCA LABS
 
P/E (TTM) x 398.8 29.2 1,366.8% View Chart
P/BV x 6.2 3.5 179.6% View Chart
Dividend Yield % 0.1 0.1 62.4%  

Financials

 FULFORD INDIA   IPCA LABS
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
IPCA LABS
Mar-18
FULFORD INDIA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs942695 135.5%   
Low Rs450400 112.5%   
Sales per share (Unadj.) Rs691.4260.2 265.7%  
Earnings per share (Unadj.) Rs11.519.0 60.4%  
Cash flow per share (Unadj.) Rs15.433.1 46.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.30.2 157.4%  
Book value per share (Unadj.) Rs380.0213.0 178.4%  
Shares outstanding (eoy) m3.90126.20 3.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.02.1 47.8%   
Avg P/E ratio x60.728.9 210.3%  
P/CF ratio (eoy) x45.316.6 273.5%  
Price / Book Value ratio x1.82.6 71.2%  
Dividend payout %17.45.3 331.0%   
Avg Mkt Cap Rs m2,71469,120 3.9%   
No. of employees `0000.413.3 3.3%   
Total wages/salary Rs m5057,359 6.9%   
Avg. sales/employee Rs Th6,073.02,477.4 245.1%   
Avg. wages/employee Rs Th1,137.4555.2 204.9%   
Avg. net profit/employee Rs Th100.7180.6 55.7%   
INCOME DATA
Net Sales Rs m2,69632,836 8.2%  
Other income Rs m125418 30.0%   
Total revenues Rs m2,82233,254 8.5%   
Gross profit Rs m-464,505 -1.0%  
Depreciation Rs m151,777 0.9%   
Interest Rs m10240 4.0%   
Profit before tax Rs m542,905 1.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m10511 1.9%   
Profit after tax Rs m452,394 1.9%  
Gross profit margin %-1.713.7 -12.5%  
Effective tax rate %17.717.6 100.5%   
Net profit margin %1.77.3 22.7%  
BALANCE SHEET DATA
Current assets Rs m1,73819,455 8.9%   
Current liabilities Rs m54510,076 5.4%   
Net working cap to sales %44.328.6 155.0%  
Current ratio x3.21.9 165.3%  
Inventory Days Days4898 49.5%  
Debtors Days Days467 6.4%  
Net fixed assets Rs m1220,260 0.1%   
Share capital Rs m39252 15.5%   
"Free" reserves Rs m1,44326,633 5.4%   
Net worth Rs m1,48226,886 5.5%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m2,07741,173 5.0%  
Interest coverage x6.713.1 51.3%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.30.8 162.8%   
Return on assets %2.66.4 40.8%  
Return on equity %3.08.9 33.9%  
Return on capital %4.310.8 40.0%  
Exports to sales %047.6 0.0%   
Imports to sales %24.514.9 164.4%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs m6594,884 13.5%   
Fx inflow Rs m1715,642 0.1%   
Fx outflow Rs m6734,884 13.8%   
Net fx Rs m-65610,759 -6.1%   
CASH FLOW
From Operations Rs m903,411 2.6%  
From Investments Rs m105-1,354 -7.7%  
From Financial Activity Rs m-14-1,304 1.1%  
Net Cashflow Rs m181753 24.0%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 11.4 33.3%  
FIIs % 0.1 25.3 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 17.4 121.8%  
Shareholders   4,783 36,892 13.0%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PFIZER  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 5-YR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS